Natural history of follicular grade 3 non-Hodgkin's lymphoma

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Follicular lymphoma grade 3 is recognized as a distinct entity in the World Health Organization classification of lymphomas. There is confusion regarding the natural history of these lymphomas, because some studies indicate an indolent behavior and others show more aggressive behavior. This review examines the biological and clinical characteristics of follicular lymphoma grade 3 and compares these characteristics with other lymphomas. RECENT FINDINGS: Several reports suggest that follicular lymphoma grade 3 has molecular and genetic characteristics that distinguish these lymphomas from other grades of follicular lymphoma. These characteristics are often more common in patients with diffuse large B-cell lymphoma than follicular lymphoma. It is impossible to make firm recommendations on management because prospective trials are lacking. Nevertheless, recent studies have demonstrated that follicular lymphoma grade 3 patients treated with anthracycline-based therapy have similar outcomes to patients with diffuse large B-cell lymphoma. SUMMARY: Patients with follicular lymphoma grade 3 should be treated with curative intent. They should receive aggressive anthracycline-based therapy combined with rituximab, which is identical to therapy used for patients with diffuse large B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalCurrent Opinion in Oncology
Volume19
Issue number5
DOIs
StatePublished - Sep 1 2007

Fingerprint

Follicular Lymphoma
Natural History
Non-Hodgkin's Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma
Anthracyclines
Molecular Biology
Therapeutics

Keywords

  • Follicular large cell lymphoma
  • Follicular lymphoma
  • Follicular lymphoma grade 3

ASJC Scopus subject areas

  • Cancer Research

Cite this

Natural history of follicular grade 3 non-Hodgkin's lymphoma. / Bierman, Philip Jay.

In: Current Opinion in Oncology, Vol. 19, No. 5, 01.09.2007, p. 433-437.

Research output: Contribution to journalReview article

@article{e7de88f9e9974e5d9e35447eabc1790e,
title = "Natural history of follicular grade 3 non-Hodgkin's lymphoma",
abstract = "PURPOSE OF REVIEW: Follicular lymphoma grade 3 is recognized as a distinct entity in the World Health Organization classification of lymphomas. There is confusion regarding the natural history of these lymphomas, because some studies indicate an indolent behavior and others show more aggressive behavior. This review examines the biological and clinical characteristics of follicular lymphoma grade 3 and compares these characteristics with other lymphomas. RECENT FINDINGS: Several reports suggest that follicular lymphoma grade 3 has molecular and genetic characteristics that distinguish these lymphomas from other grades of follicular lymphoma. These characteristics are often more common in patients with diffuse large B-cell lymphoma than follicular lymphoma. It is impossible to make firm recommendations on management because prospective trials are lacking. Nevertheless, recent studies have demonstrated that follicular lymphoma grade 3 patients treated with anthracycline-based therapy have similar outcomes to patients with diffuse large B-cell lymphoma. SUMMARY: Patients with follicular lymphoma grade 3 should be treated with curative intent. They should receive aggressive anthracycline-based therapy combined with rituximab, which is identical to therapy used for patients with diffuse large B-cell lymphoma.",
keywords = "Follicular large cell lymphoma, Follicular lymphoma, Follicular lymphoma grade 3",
author = "Bierman, {Philip Jay}",
year = "2007",
month = "9",
day = "1",
doi = "10.1097/CCO.0b013e3282c9ad78",
language = "English (US)",
volume = "19",
pages = "433--437",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Natural history of follicular grade 3 non-Hodgkin's lymphoma

AU - Bierman, Philip Jay

PY - 2007/9/1

Y1 - 2007/9/1

N2 - PURPOSE OF REVIEW: Follicular lymphoma grade 3 is recognized as a distinct entity in the World Health Organization classification of lymphomas. There is confusion regarding the natural history of these lymphomas, because some studies indicate an indolent behavior and others show more aggressive behavior. This review examines the biological and clinical characteristics of follicular lymphoma grade 3 and compares these characteristics with other lymphomas. RECENT FINDINGS: Several reports suggest that follicular lymphoma grade 3 has molecular and genetic characteristics that distinguish these lymphomas from other grades of follicular lymphoma. These characteristics are often more common in patients with diffuse large B-cell lymphoma than follicular lymphoma. It is impossible to make firm recommendations on management because prospective trials are lacking. Nevertheless, recent studies have demonstrated that follicular lymphoma grade 3 patients treated with anthracycline-based therapy have similar outcomes to patients with diffuse large B-cell lymphoma. SUMMARY: Patients with follicular lymphoma grade 3 should be treated with curative intent. They should receive aggressive anthracycline-based therapy combined with rituximab, which is identical to therapy used for patients with diffuse large B-cell lymphoma.

AB - PURPOSE OF REVIEW: Follicular lymphoma grade 3 is recognized as a distinct entity in the World Health Organization classification of lymphomas. There is confusion regarding the natural history of these lymphomas, because some studies indicate an indolent behavior and others show more aggressive behavior. This review examines the biological and clinical characteristics of follicular lymphoma grade 3 and compares these characteristics with other lymphomas. RECENT FINDINGS: Several reports suggest that follicular lymphoma grade 3 has molecular and genetic characteristics that distinguish these lymphomas from other grades of follicular lymphoma. These characteristics are often more common in patients with diffuse large B-cell lymphoma than follicular lymphoma. It is impossible to make firm recommendations on management because prospective trials are lacking. Nevertheless, recent studies have demonstrated that follicular lymphoma grade 3 patients treated with anthracycline-based therapy have similar outcomes to patients with diffuse large B-cell lymphoma. SUMMARY: Patients with follicular lymphoma grade 3 should be treated with curative intent. They should receive aggressive anthracycline-based therapy combined with rituximab, which is identical to therapy used for patients with diffuse large B-cell lymphoma.

KW - Follicular large cell lymphoma

KW - Follicular lymphoma

KW - Follicular lymphoma grade 3

UR - http://www.scopus.com/inward/record.url?scp=34548410018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548410018&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3282c9ad78

DO - 10.1097/CCO.0b013e3282c9ad78

M3 - Review article

VL - 19

SP - 433

EP - 437

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 5

ER -